NO20060641L - Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaser - Google Patents
Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaserInfo
- Publication number
- NO20060641L NO20060641L NO20060641A NO20060641A NO20060641L NO 20060641 L NO20060641 L NO 20060641L NO 20060641 A NO20060641 A NO 20060641A NO 20060641 A NO20060641 A NO 20060641A NO 20060641 L NO20060641 L NO 20060641L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compounds
- inhibitors
- receptor tyrosine
- tyrosine kinases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår forbindelser med formel (I), hvor Z er -NH-, -O- eller -S-; Rrepresenterer brom eller klor; Rrepresenterer C_alkoksy eller hydrogen; Rer valgt fra én av de følgende tre grupper: (i) C^Xhvor Xog Qer som definert her; (ii) QW- hvor Qog Wer som definert her; og (iii) Q^W^d.salkylX1 hvor X, Wog Qer som definert her;og salter derav; anvendelse av dem ved fremstilling av et medikament for anvendelse for produksjon av en antiangiogen og/eller vaskulær permeabilitetsreduserende effekt hos varmblodige dyr; fremgangsmåter for fremstilling av slike forbindelser; farmasøytiske preparater inneholdende en forbindelse med formel I eller et farmasøytisk akseptabelt salt derav og metoder for behandling av sykdomstilstander som involverer angiogenese ved administrering av en forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav. Forbindelsene med formel (I) hemmer virkningene av VEGF, en egenskap verdifull ved behandling av flere sykdomstilstander omfattende kreft og revmatoid artritt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0318423.1A GB0318423D0 (en) | 2003-08-06 | 2003-08-06 | Chemical compounds |
PCT/GB2004/003393 WO2005013998A1 (en) | 2003-08-06 | 2004-08-05 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060641L true NO20060641L (no) | 2006-05-03 |
Family
ID=27839733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060641A NO20060641L (no) | 2003-08-06 | 2006-02-09 | Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaser |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070027145A1 (no) |
EP (1) | EP1653965A1 (no) |
JP (1) | JP2007501212A (no) |
KR (1) | KR20060058781A (no) |
CN (1) | CN1863534A (no) |
AU (1) | AU2004262982A1 (no) |
BR (1) | BRPI0413280A (no) |
CA (1) | CA2534422A1 (no) |
GB (1) | GB0318423D0 (no) |
IL (1) | IL173483A0 (no) |
MX (1) | MXPA06001394A (no) |
NO (1) | NO20060641L (no) |
WO (1) | WO2005013998A1 (no) |
ZA (1) | ZA200601030B (no) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE549329T1 (de) * | 2002-02-01 | 2012-03-15 | Astrazeneca Ab | Chinazoline verbindungen |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
SG10201510586PA (en) | 2008-06-30 | 2016-01-28 | Mesoblast Inc | Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy |
JP2013514379A (ja) * | 2009-12-15 | 2013-04-25 | ニユーロツプ・インコーポレイテツド | 神経障害の治療のための化合物 |
AR092289A1 (es) * | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
CN105330653A (zh) | 2014-08-11 | 2016-02-17 | 石药集团中奇制药技术(石家庄)有限公司 | 喹唑啉衍生物 |
US9854482B2 (en) * | 2015-04-21 | 2017-12-26 | International Business Machines Corporation | Controlling a delivery of voice communications over a cellular data network or a wireless network based on user's profile |
CA3012718A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
CN106565681B (zh) * | 2016-11-10 | 2019-07-09 | 中国医学科学院放射医学研究所 | 含硝基咪唑基团的苯胺喹唑啉类化合物及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
DK0880508T3 (da) * | 1996-02-13 | 2003-06-30 | Astrazeneca Ab | Quinazolinderivater som VEGF-inhibitorer |
ATE211134T1 (de) * | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP1119567B1 (en) * | 1998-10-08 | 2005-05-04 | AstraZeneca AB | Quinazoline derivatives |
HU228964B1 (en) * | 1999-02-10 | 2013-07-29 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors, process for their preparation and medicaments containing them |
ES2265998T3 (es) * | 1999-11-05 | 2007-03-01 | Astrazeneca Ab | Derivados de quizazolina como inhibidores de vegf. |
WO2001077085A1 (en) * | 2000-04-07 | 2001-10-18 | Astrazeneca Ab | Quinazoline compounds |
-
2003
- 2003-08-06 GB GBGB0318423.1A patent/GB0318423D0/en not_active Ceased
-
2004
- 2004-08-05 MX MXPA06001394A patent/MXPA06001394A/es unknown
- 2004-08-05 EP EP04801817A patent/EP1653965A1/en not_active Withdrawn
- 2004-08-05 BR BRPI0413280-7A patent/BRPI0413280A/pt not_active IP Right Cessation
- 2004-08-05 KR KR1020067002552A patent/KR20060058781A/ko not_active Application Discontinuation
- 2004-08-05 WO PCT/GB2004/003393 patent/WO2005013998A1/en active Application Filing
- 2004-08-05 CN CNA2004800288013A patent/CN1863534A/zh active Pending
- 2004-08-05 AU AU2004262982A patent/AU2004262982A1/en not_active Abandoned
- 2004-08-05 JP JP2006522409A patent/JP2007501212A/ja not_active Withdrawn
- 2004-08-05 CA CA002534422A patent/CA2534422A1/en not_active Abandoned
- 2004-08-05 US US10/566,841 patent/US20070027145A1/en not_active Abandoned
-
2006
- 2006-01-31 IL IL173483A patent/IL173483A0/en unknown
- 2006-02-03 ZA ZA200601030A patent/ZA200601030B/en unknown
- 2006-02-09 NO NO20060641A patent/NO20060641L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2004262982A1 (en) | 2005-02-17 |
KR20060058781A (ko) | 2006-05-30 |
CN1863534A (zh) | 2006-11-15 |
US20070027145A1 (en) | 2007-02-01 |
WO2005013998A1 (en) | 2005-02-17 |
BRPI0413280A (pt) | 2006-10-10 |
MXPA06001394A (es) | 2006-05-19 |
JP2007501212A (ja) | 2007-01-25 |
CA2534422A1 (en) | 2005-02-17 |
ZA200601030B (en) | 2007-05-30 |
IL173483A0 (en) | 2006-06-11 |
GB0318423D0 (en) | 2003-09-10 |
EP1653965A1 (en) | 2006-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060641L (no) | Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaser | |
NO20060650L (no) | Kinazolinderivater som angiogeneseinhibitorer | |
NO20062763L (no) | Pyrrolotriazinforbindelser som kinaseinhibitorer | |
NO20090025L (no) | Pyrrolotriazinkinaseinhibitorer | |
MA33540B1 (fr) | Dérivés de la pyridine et de la pyrazine en tant que modulateurs de la protéine kinase | |
ATE365742T1 (de) | 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren | |
BRPI0515499A (pt) | derivados de piridina para a inibição de estearoil-coa-desaturase humana | |
UA99361C2 (uk) | ТРИАЗИНИ ЯК ІНГІБІТОРИ PІ3-КІНАЗИ І mTOR | |
ATE437872T1 (de) | Proteinkinaseinhibitoren | |
NO20060195L (no) | Kinolylamidderivater som CCR-5-antagonister | |
MXPA04004301A (es) | Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa. | |
TNSN07022A1 (fr) | Derives de pyridine | |
EA201000552A1 (ru) | Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
BR0310106A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
NO20070258L (no) | Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer | |
NO20065320L (no) | Imidazolderivater anvendt som tafiainhibitorer | |
NO20076196L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
PE20081393A1 (es) | Derivados de quinolina como inhibidores de csf-1r | |
NO20050573L (no) | 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler | |
DE60129934D1 (de) | Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie | |
BRPI0409255A (pt) | derivados de ácido 2-(8,9-dioxo-2,6-diazabi-ciclo(5.2.0)non-1(7)-en-2-il)alquil fosfÈnico e seu uso como antagonistas de receptores de d-asparto de -n-metila (nmda) | |
NO20060718L (no) | Substituerte tiofoner og deres anvendelse | |
NO20063865L (no) | Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |